R-Japan Leads Japan’s Regenerative Medicine Technology with Korean Autologous Adipose Tissue-Derived Culture-Expanded Stem Cells
- SEOUL, South Korea–R-Japan, an affiliated company of Nature Cell (KOSDAQ: 007390), announced the results of its business performance in 2016.
In 2016 R-Japan cultured and supplied a total of 1,055.9 billion stem cells to 5 affiliated hospitals including Nishihara Clinic. The company conducted regenerative medical treatment more than 3,500 times and achieved sales of KRW10.4 billion and generated a profit of KRW1.6 billion.
The patients who received the regenerative medical treatment using the stem cells supplied by R-Japan did not have any side effects. These results have been officially reported to the Ministry of Health, Labor and Welfare of Japan.
Moreover, the effects of stem cell treatment of degenerative arthritis, critical limb ischemia, autoimmune disease and skin care are being gradually acknowledged; R-Japan reported the number of medical treatments for degenerative arthritis exceeded 650 with a very high satisfaction rate with regards to its therapeutic effect.
R-Japan is promoting the expansion of affiliated medical institutions in 27 regions including Hokkaido, Kansai, and Kyushu, the company expects to start the stem cell regenerative medical treatment in 2017. Moreover, the company is planning to expand the area of medical treatment to anti-aging and Alzheimer’s disease. This year the company expects to perform regenerative medical treatment more than 5,000 times and supply cells which will be worth more than KRW1.5 trillion.
From this March production processes will be allocated to Nature Cell and the affiliated company R Bio, which received permission for manufacturing from the Ministry of Health, Labor and Welfare of Japan. Japan BioStar Stemcell Research Institute (Director: Jeong-chan Ra) will be established in the KOBE Biomedical Innovation Cluster.
R-JAPAN Co., Ltd. is the leader in biotechnology, the company specializes in manufacturing of mesenchymal stem cells for regenerative therapy using the stem cell technology of Biostar Stem Cell Research Institute in Korea. R-Japan’s own technology is to isolate, multiply, and store adult mesenchymal stem cells ensuring genetic integrity. R-Japan currently cultures approximately 1,000 cases per month and has been recognized by many medical institutions. Since the opening of the stem cell processing facility R-Japan has cultured 5,860 billion cells for 24,293 patients.
Park, Hye rim